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Aplasia
A frequent clinical and haematological 
question is what pathological process has 
caused the full blood count result, also 
sometimes called the haemogram, to become 
abnormal? This is particularly important when 
one or other peripheral value is significantly 
raised or, conversely, reduced. In the latter 
instance involvement of a single lineage, 
giving rise to anaemia or thrombocytopenia, 
has vastly different implications than when 
all three cell types are below normal – the 
entity of pancytopenia. The cardinal first step 
is to separate global bone marrow failure or 
aplasia from hypercellularity with ineffective 
production or intramedullary destruction, 
also known as shunting, that occurs with 
vitamin B12 and folate deficiency. This needs 
to be distinguished from the myelodysplastic 
(preleukaemic) syndromes. The variability 
in presentation can be misleading and, to 
rapidly arrive at the correct interpretation 
of the patient’s problem, it is prudent to seek 
explanation in how normal (i.e. physiological) 
structure and particularly function are 
disturbed – causation or pathophysiology.
Physiology
The bone marrow continuously produces, 
and delivers daily, to the circulating blood 
2.5 billion new red cells, 100 - 500 million 
granulocytes and a further vast number 
of lymphocytes, together with 2.5 billion 
platelets at a rate to exactly match loss by 
the body through utilisation and natural 
ageing or death in the process, described 
as apoptosis. These balanced processes 
dynamically and rapidly respond to any 
changes in the internal environment where 
individual lineages selectively accelerate 
singly or in any appropriate combination, 
to maintain levels within narrow ranges 
and so protect tissue or organ functional 
integrity. 
The spongy medullary cavity, sandwiched 
between layers of dense supporting cortical 
bone, is where the immunohaematopoietic 
stem cells home to receptors through 
particular patterns of adhesion molecules, 
grow and mature in specialised endosteal 
areas called niches (Fig. 1). In this specialised 
microenvironment they are nurtured by 
the supporting architecture derived largely 
from mesenchyme and its derivatives with a 
wide range of locally secreted growth factors 
(Fig. 2).
With appropriate stimuli the first division 
leads to replenishment of this stem cell pool 
as a unique and defining characteristic. The 
daughter cell undergoes commitment to 
blood formation via the haemangiocytoblast 
that can give rise to vascular endothelium 
and the full range of haematopoietic 
cells, collectively known as the haematon. 
Differentiation separates lineages – one will 
result in both B and T lymphocytes that 
fulfil immunological function. The second, 
collectively described as myeloid, generates 
red cells or the erythron, granulocytes and 
monocytes as well as megakaryocytes from 
which platelets will ultimately be derived 
(Fig. 3). Within each lineage the earliest 
progeny are known as progenitors and 
not morphologically identifiable, needing 
the use of in vitro laboratory culture 
techniques. These give rise to precursors 
that are microscopically recognisable as 
normoblasts comprising the red cells series 
that include erythroid islands (Fig. 4) 
This is the first in our third series of clinical vignettes that are centred on everyday 
presentations. Each emphasises practical aspects of team-based care, having relevance 
for general practitioners, specialists and paramedical professionals alike. Disorders 
arising in blood and bone marrow result in some of the commonest symptoms and 
signs for which patients seek medical advice. A carefully taken history and meticulous 
physical examination, complemented by thoughtful and judicious use of laboratory tests, 
provide the clinical basis for a working diagnosis. Advanced haematology may be needed 
to extend evaluation to the bone marrow and plasma while supplementary imaging 
or radionuclide technology further links primary care practitioner or specialist to the 
experienced haematologist. Such a multidisciplinary and fully interactive approach offers 
the preferred way to problem solving and optimum management.
Fig. 1. The bone marrow niche.
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central to regulation of iron traffic between 
the stores in macrophages and haemoglobin 
synthesis in this population. 
At the same time, and occurring 
approximately 3 times more frequently, 
a range of granulocytes and monocytes 
develop that acquire quite different 
cytomorphological characteristics during 
their growth (Fig. 5). Megakaryocytes are 
also formed during myelopoiesis and these 
ultimately liberate cytoplasmic contents into 
the circulation as platelets.
Proliferation is best examined by 
focusing on granulocytes. Consecutive 
phases vary, giving rise to a kinetically 
distinct mitotic pool in which numbers 
expand to include the myeloblasts, 
progranulocytes and myelocytes  – loosely 
referred to as the fixed components of the 
microenvironment.  Maturation occurs in 
a post-mitotic compartment, and is made 
up of metamyelocytes, band forms and 
mature neutrophils, and allows the cells 
to reach full functional state prior to the 
release into the circulation: also called the 
labile compartment or pool. Apoptosis, 
intramedullary death that is sometimes 
known as shunting, provides a system 
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Fig. 2. Growth or stimulatory factors. The orderly development, and then delivery of mature cells to the peripheral blood is moderated by 
changing patterns of migration through the marrow. An array of molecules, or peptides, has a distinct pattern of expression during the various 
stages of differentiation, proliferation and maturation. These steps are coupled with alterations in adhesion factors that govern release from the 
niche and balance this exactly to intramedullary destruction or apoptosis, as dictated by physiological requirements. The focused activity of these 
cytokines can be recapitulated with commercially available equivalents to selectively drive each line in therapy: e.g. erythropoietic stimulating 
factors for erythrocytes and granulocyte or monocyte stimulating agents (G:CSF) in the case of these two lineages.
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of quality control in which about 15% of 
the daily production is removed by the 
phagocytic cells of the reticuloendothelial 
system and never circulate – a similar 
pattern is seen in the other cell lines.
These stages can be disordered at a number 
of different levels and may affect one or more 
lines. Global production failure defines 
aplasia while a single lineage is described as 
cytopenia. This is a fundamental distinction 
upon which is based classification that 
will, in turn, dictate further investigation 
en route to individualised comprehensive 
management.
Pathophysiology
Clinical1
Many individuals with aplasia, particularly in 
the early phases or during disease evolution, 
are asymptomatic. Presentation is typically 
fatigue, with decreasing effort tolerance 
and palpitations that correlates roughly 
with the rate as well as fall in haemoglobin 
level.2 Less commonly pale skin, headache 
and dizziness are the first warning signs. 
Recurrent bacterial infections occur due to 
neutropenia that may be compounded by 
leucocyte dysfunction. 
Low platelet counts result in a primary 
haemostatic defect with prolonged bleeding 
from cuts and less often accompanied by 
epistaxis while oozing from the gums is 
an early warning sign.3 Once levels drop 
below 10 or 15 x 109/l mucocutaneous 
bruising, particularly at sites of relatively 
minor injury, is characteristic and may be 
aggravated by concurrent use of antiplatelet 
drugs such as aspirin or non-steroidal anti-
inflammatory agents. 
Haematological
The first step is meticulous examination of 
peripheral blood count values to make the 
initial crucial distinction between single 
cytopenia such as anaemia, low white 
count or reduced platelets, in contrast to 
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Fig. 3. Kinetics of blood cell generation – the concept of pools or compartments. Totipotentiality is found only when sperm fuses with ovum to 
create a zygote. Immediately there is restriction described as pluripotentially governing all tissue and organ development, well-exemplified in 
immunohaematopoiesis. Here the different lineages diverge into lymphoid and myeloid with the latter further narrowed down to give rise to red 
cells, the platelet-megakaryocyte system in parallel with earliest monocytes and granulocytes.
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pancytopenia in which all the levels are sub-
normal or pancytopenia is a problem. 
It is difficult to overemphasise the 
importance of supplementing instrument-
generated figures in the haemogram by 
careful scrutiny of a well-prepared blood 
film or smear. Cytomorphologically, the 
distribution of mature cells in the peripheral 
blood can be enumerated in a differential 
leucocyte count. Particularly relevant at this 
point is establishing total marrow activity 
as reflected in the reticulocyte count, 
corrected for the haemoglobin level, to 
generate the production index that provides 
a ready clinical assessment to quantitate 
overall function of the haematon reflected 
primarily in the red cells series.4
With this information it is logical to directly 
examine the bone marrow by means of 
aspiration coupled with trephine biopsy (Fig. 
6). This remains the central investigation to 
secure the initial working diagnosis. 
Once a production defect due to global 
marrow failure or aplasia is confirmed, a 
number of different explanations arise for 
loss of precursor cells in the marrow (Fig. 
7). Here the experienced haematologist is 
needed to direct confirmatory investigations 
as a basis for treatment.
Causation
Of the inherited disorders, Fanconi 
anaemia may present late and with 
minimal anatomical abnormalities which 
can be overlooked, making recognition 
of the syndrome difficult. With the 
advent of molecular testing telomerase 
mutations and other genetic defects are 
becoming diagnosable. Acquired injuries 
include irradiation and a wide spectrum 
of cytotoxic drugs and industrial toxins, 
among which are benzene and a number 
of relatively commonly used medications. 
A surprising range of viral infections have 
been incriminated, including hepatitis, 
parvovirus and, in sub-Saharan Africa of 
particular significance, HIV (Fig. 8). 
Once these possibilities have been 
excluded immune-mediated mechanisms, 
supported by experimental and clinical 
observations, become the basis for 
selection of suppressive interventions. 
These range from antithymocyte 
globulin, with or without cyclosporin, 
determined by severity of disease. Other 
choices are mycophenolate mofetil and 
cyclophosphamide.5
Diagnostic algorithm
It cannot be over-emphasised that this 
possibility requires immediate referral 
to an appropriate academic centre, so 
avoiding problems with both under- 
and over-diagnosis and preventing 
inappropriate treatment or side-effects.
Fig. 6. The trephine biopsy. Normally between 
60% and 80% of the marrow is occupied by 
blood-forming tissue with the architectural 
arrangement best appreciated from trephine 
biopsy shown in the top panel. In contrast, loss 
of haematopoiesis depletes these precursors, 
leaving residual stroma comprising delicate 
reticulin, lymphocytes, monocytes and 
abundant fat spaces.
Ineffective haematopoiesis
B12 or folate deficiency
Myelodysplasia
Severe infections
Extensive infiltration
Malignancy
Fibrosis 
Aplasia 
Congenital 
Acquired
Fig. 7. Pancytopenia due to marrow failure. 
Diagnosis may be reflected in the peripheral 
blood smear. The cardinal investigation is 
examination of the bone marrow aspiration 
and trephine biopsy.
Fig. 4. Erythroblastic island. Iron traffic 
to maturing red cell population, the 
normoblasts, broadly described as the 
erythron, are in part furnished by recovery 
from the diet via enterocytes in the small 
bowel. Simultaneously, recycling of this trace 
metal from effete red cells in the macrophage 
system is exemplified by those in the bone 
marrow. The regulation is genetically 
determined and modulated by expression of 
the iron exporter known as ferroportin. The 
latter is under surveillance and regulation 
by the master regulator – the hepatic peptide 
known as hepcidin.
Fig. 5. Bone marrow precursors – aspirated 
sternal sample. The ratio of myeloid to 
erythroid cells (shown by arrow), or the 
M-E ratio is physiologically 3 to 1. A range 
of granulocytes are recognisable from 
neutrophils to the earlier myelocytes (shown 
by *) distinguished by azurophilic granules 
in the cytoplasm. Megakaryocytes are large 
and prominent (not present). Both erythroid 
and myeloid lines undergo varying degrees 
of maturation prior to release into the 
circulation.
*
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While symptomatic anaemia or  thrombo-
cytopenic mucocutaneous bleeding may be 
the presenting symptoms, the most ominous 
association is with recurrent bacterial 
infections as a result of profound neutropenia 
and dysfunctional innate immune system. 
It is impossible to sufficiently stress the 
importance of a thorough history and clinical 
examination preceding laboratory studies.6 
Disease severity is characterised after 
confirmation on bone marrow aspiration 
and scrutiny of the trephine biopsy (Fig. 9). 
This also excludes inherited bone marrow 
failure syndromes, hairy cell and chronic 
lymphocytic leukaemia, collagen vascular 
diseases and particularly systemic lupus 
erythematosus. 
Do not overlook the presence of 
abnormal populations or clones due to 
paroxysmal nocturnal haemoglobinuria 
or myelodysplasia, the impact of HIV or 
infiltrative lesions causing hypersplenism 
on the basis of congestive splenomegaly. 
However, in these cases the marrow is not 
devoid of haematopoietic tissue.
Therapeutic decisions and 
management
Supportive care is often adequate in mild 
and stable to improving forms, anticipating 
repopulation of the marrow where recovery 
is variable and independence may occur 
from transfusion. This approach requires 
detailed record-keeping with antigen-
reduced packed red cells sufficient for 
symptomatic relief given with chelation 
therapy to avoid iron overload. 
Granulocyte stimulatory peptides have 
limited value since the precursor cells are 
generally absent. However, be aware of 
the local prevalence of specific bacterial 
pathogens in order to treat infections 
empirically where necessary. An infectious 
disease or microbiology consultant on the 
team is invaluable. Thrombocytopenia is 
also challenging and replacement should be 
limited to single apheresis units given only to 
maintain haemostasis. The local practice of 
replacement without documenting response 
should be avoided, as such practices may 
accelerate isoimmunisation. The major 
emphasis is to restrict this period and 
proceed to specific curative interventions as 
rapidly as necessary. 
Allogeneic immunohaematopoietic stem 
cell transplantation from a fully matched 
sibling is preferable in severe forms of 
the disease. Where this is not possible a 
matched unrelated volunteer donor is the 
next choice. Depending on conditioning 
programmes and other variations in these 
procedures, complications range from 
rejection through acute and possibly 
subsequent chronic graft-versus-host 
disease to even graft failure. Nevertheless, 
in younger individuals cure rates have 
continually improved over the years and 
currently exceed 90%.2,3,6
Immunosuppressive regimens have emerged 
over the years with varying responses to 
regimens that include antithymocyte globu-
lin through high-dose corticosteroids and 
cyclosporin or novel agents. Preliminary 
data suggest that all three products in com-
Cytotoxic drugs and radiation
Idiosyncratic drug reaction
Chloramphenicol
Non-steroidal anti-inflammatory
Sulphonamides 
Industrial toxins
Benzene 
Viral infections
Hepatitis 
HIV
Epstein-Barr virus
Immune disorders
Systemic lupus erythematosus
Miscellaneous 
Paroxysmal nocturnal haemoglobinuria
Thymic tumours
Pregnancy 
Idiopathic or primary
Fig. 8. Causes of bone marrow aplasia. 
In some cases the cause is apparent and 
predictably reversible – only careful 
observation is needed. In others it may be 
obscure and have an immunological basis. 
The relevance of accurate diagnosis is choice 
of therapy and options extend from support 
and monitoring to active intervention ranging 
from immunosuppression to allogeneic bone 
marrow transplantation.
Fig. 9. Diagnostic criteria and grading for aplasia. The correlation of survival is with absolute 
neutrophil count at diagnosis. Where this is under 0.2 x 109 /l outcome is substantially and 
significantly inferior predicating a more aggressive approach to interventions and moving 
therapeutic options towards early immunohaematopoietic stem cell allogeneic transplantation. 
ANC = absolute neutrophil count; 500 ANC = 0.5 x 109/l.
Moderate aplasia
Bone marrow cellularity <30%
Absence of severe pancytopenia
Depression of at least two of three blood elements below normal
Severe aplastic aplasia
A bone marrow biopsy showing <25% of normal cellularity 
or
A bone marrow biopsy showing <50% normal cellularity in which fewer  
than 30% of the cells are haematopoietic
And at least two of the following are present:
Absolute reticulocyte count <40 000/microliter
Absolute neutrophil count (ANC) <500/microliter
Platelet count <20 000/microliter
Very severe aplasia
The criteria for severe aplastic anaemia are met and the ANC is <200/microliter
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bination may have a better outcome. Late 
relapse and clonal malignant disease arise 
in a quarter of those treated. Additionally, 
in comparison to transplanted individuals, 
while a good life is possible, cure remains 
infrequent despite prolonged cyclosporin 
and steroid maintenance.5
 
These realities should be fully understood 
by referring doctors and mandate access to 
experienced multidisciplinary clinics who 
regularly audit and report outcome. 
Alternative or innovative options include 
unconfirmed observations that a single 
course of cyclophosphamide may prolong 
survival in about half the patients. 
Attempts to combine this with other 
immunosuppressive regimens, particularly 
antithymocyte globulin, were unsuccessful 
and further evaluation of this approach 
is awaited. Another promising approach, 
currently unconfirmed, is response to a 
monoclonal antibody that binds to the 
interleukin-2 receptor, thereby modulating 
T-cell-mediated immunosuppression. 
Current practice 
The treatment of choice, when a suitable 
donor is available, remains a fully matched 
immunohaematopoietic stem cell transplant 
from a sibling as an early priority. When this 
is not possible alternative options include 
timeous use of matched unrelated volunteer 
donors. Success depends upon performance 
status and absence of significant co-
morbidity. 
Conditioning is immunosuppressive rather 
than myeloablative. Cyclophosphamide with 
antithymocyte globulin and fludarabine 
produces a survival rate of approximately 
70% at 15 years in a cohort under 20 years 
of age. In older patients, certainly up to 60, 
good results are possible even following 
previous treatment. 
One major point is the need to blunt po-
tential graft-versus-host disease. Campath 
monoclonal antibodies, particularly ex vivo 
or using in-the-bag technique, have shown 
success.7 These results were from centres 
with experienced multidisciplinary teams. 
Pure red cell aplasia
In adults this is acquired, with profound 
anaemia, characteristically without reticu-
locytes in the blood and erythroid precur-
sors absent from the marrow while the other 
elements are preserved.
Pathophysiology
The total loss of erythropoiesis is believed 
to be immune-mediated by both antibody 
and T-cells at a point of development prior 
to the pro-erythroblasts. Additionally there 
may be humorally directed inhibition 
of erythropoietin but the alternative 
explanation is that erythropoietin-
stimulating activity leads to the loss of 
these precursors. In many instances there 
is a specific attack on the precursors by 
parvovirus B19 and increasing concern of 
an underlying early myelodysplasia. 
The aetiology may be primary or secondary 
(Fig. 10).
Diagnosis depends upon usually severe 
degrees of anaemia that is, initially at least, 
asymptomatic but typically preceded by 
fall in exercise tolerance and relentlessly 
progressive fatigue. Reticulocytes are absent 
but the remainder of the peripheral blood 
findings are normal. 
Haematology 
Bone marrow aspiration and particularly 
trephine biopsy are diagnostic. Interestingly 
there may be giant pro-normoblasts in the 
marrow that many consider pathognomonic 
(Fig. 11).  
In evaluating associated and possibly 
causative mechanisms, use tomography of the 
chest to exclude thymoma, flow cytometry 
to identify large granular lymphocyte 
proliferation and cytogenetics together with 
a fluorescent in situ hybridisation panel to 
Primary
Associated with thymoma in 10 - 15% of cases
Idiopathic causes
Secondary
Neoplasia
Chronic leukaemia, leukaemia, lymphomas; large granular lymphocytic proliferative 
disorders; prodrome to myelodysplastic syndromes
Systemic lupus erythematosus or rheumatoid arthritis
Associated with pregnancy and autoimmune diseases
Drugs
Phenytoin, chlorpropamide, zidovudine (AZT), trimethoprimsulfamethoxazole, isoniazid
Infections
Infectious mononucleosis, viral hepatitis, parvovirus infection, HIV
Fig. 10. Causation of red cell aplasia. The majority of cases have no demonstrable associated 
pathology and are therefore momentarily accepted as idiopathic or primary. It is nevertheless 
important to search carefully for possible causes – particularly if they are reversible.
Fig. 11. Bone marrow failure due to 
parvovirus B19 infection.  This particular 
and unusual morphological feature is 
distinctive and regarded by many as unique, 
signalling the underlying causation as that of 
this particular infection.
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avoid overlooking myelodysplasia as well as 
antibody tests for parvovirus. Ferrokinetic 
studies demonstrate selective absence of 
erythropoiesis but these investigations are 
still largely in a research setting. 
Treatment
Treatment requires antigen-reduced packed 
red cells to control symptoms, and iron over-
load should be diminished by concurrent use 
of chelation therapy. With an accurate diag-
nosis the course may be self-limiting, includ-
ing parvovirus B19 infections, and patients 
can be managed expectantly, although intra-
venous gammaglobulin remains an option, 
particularly in those associated with HIV.
Pathophysiologically the explanation is 
an inability of the immune system to clear 
the offending virus. In refractory cases 
interventions parallel those for aplastic 
anaemia, with significant response rates 
following immunosuppression, particularly 
with antithymocyte globulin and 
prednisone, and possibly in combination 
with anti-CD 20 monoclonal antibody, 
among other therapeutic possibilities.
Conclusion
As for aplasia, this latter entity is also 
relatively uncommon but requires 
consideration in patients whose anaemia 
is otherwise not readily explained. 
Distinction is necessary from the more 
common nutritional deficiencies or the 
anaemia of chronic disorders where 
marrow findings are usually diagnostic. 
Once the diagnosis is established, the 
importance of protocol management, 
preferably on clinical trial by an accredited 
multidisciplinary group in an academic 
centre of excellence, is regarded worldwide 
as standard of care.
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Single suture
Fingertip tingle enhances a surgeon’s sense of touch
Our fingers are precision instruments, but there are plenty of things they are not sensitive enough to detect. Now we can augment their 
talents – using wearable electronic fingertips that provide tingling feedback about whatever we touch.
John Rogers of the University of Illinois at Urbana-Champaign and colleagues have designed a flexible circuit that can be worn over the 
fingertips. It contains layers of gold electrodes just a few hundred nanometres thick, sandwiched between layers of polyimide plastic to 
form a ‘nanomembrane’. This is mounted on a finger-shaped tube of silicone rubber, allowing one side of the circuit to be in direct contact 
with the fingertips. On the other side, sensors can be added to measure pressure, temperature or electrical properties such as resistance.
People wearing the device receive electrotactile stimulation – a tingling sensation caused by a small voltage applied to the skin. The size 
of the voltage is controlled by the sensor and varies depending on the properties of the object being touched.
Surgical gloves are one potential application. Rogers, who worked with colleagues at Northwestern University in Evanston, Illinois, and 
Dalian University of Technology in China, says gloves fitted with the nanomembrane could sense the thickness or composition of tissue 
via its electrical properties. A surgeon could also whittle away at the tissue using a high-frequency alternating current supplied by a 
battery attached at the wrist and delivered via the nanomembrane itself, says Rogers.
Fiorenzo Omenetto at Tufts University in Medford, Massachusetts, is impressed. ‘The work sets the stage for a new generation of devices,’ 
he says.
There are applications beyond surgery, too. MC10, the company commercialising the technology, is running animal trials of a 
nanomembrane ‘sock’ that can be wrapped around the heart. This provides a 3D map of its electrical activity, useful in treating irregular 
heartbeat.
MC10 is also working with medical device company Medtronic to use the membrane inside the heart, sending it in on a limp balloon, 
which is then inflated to push the membrane onto the heart’s interior walls.
Rogers says MC10 is also collaborating with sportswear firm Reebok on a product to be launched by the end of this year. The aim is to 
build a ‘body-worn piece of electronics’ designed for contact sports, although Rogers declined to say exactly how it will be used.
New Scientist, 10 August 2012, online
